Key result
Thrombolytic therapy in acute myocardial infarction is associated with intracranial hemorrhage in 0.1% to 1.4% of patients, while thromboembolic stroke occurs in up to 2.4% of untreated patients.
Why the study?
What are the incidence, risk factors, and management strategies for intracranial hemorrhage complicating acute myocardial infarction treated with thrombolytic therapy?
What are the incidence, risk factors, and management strategies for intracranial hemorrhage complicating acute myocardial infarction treated with thrombolytic therapy?
This review highlights that intracranial hemorrhage is the most common form of stroke in AMI patients receiving thrombolytics (0.1-1.4%), and outlines risk factors and hematologic management strategies.
Answers are grounded in this paper and cite their sources.
ICH risk with thrombolytics in AMI warrants individualized assessment; leaves open optimal prevention strategies pending prospective data.
Cerebrovascular accidents are one of the most serious causes of morbidity in patients sustaining an acute myocardial infarction. In patients who do not receive thrombolytic therapy, the most common form of stroke is thromboembolic, occurring in up to 2.4% of patients, predominantly in those sustaining large anterior infarctions. In patients receiving thrombolytic therapy, intracranial hemorrhage is the most common form of stroke, occurring in 0.1% to 1.4%. Predisposing conditions for intracranial bleeding include low body weight, female sex, advanced age, use of oral anticoagulant medication before the administration of lytic therapy, diastolic blood pressure greater than 110 mm Hg, and the specific thrombolytic agent administered. Hematologic management of the patient sustaining a hemorrhagic cerebrovascular accident should include (1) discontinuance of thrombolytic therapy, anticoagulants, and antiplatelet agents and (2) infusion of cryoprecipitate to replenish fibrinogen. In certain cases, administration of fresh frozen plasma, protamine sulfate, and exogenous platelets may be required. Finally, evacuation of the hematoma may provide the most definitive form of treatment in selected cases.
No takes yet. Share an insight, caveat, or question.
Conrad et al. (1997) conducted a review in Acute myocardial infarction. Thrombolytic therapy vs. No thrombolytic therapy was evaluated on Intracranial hemorrhage or thromboembolic stroke. Thrombolytic therapy in acute myocardial infarction is associated with intracranial hemorrhage in 0.1% to 1.4% of patients, while thromboembolic stroke occurs in up to 2.4% of untreated patients.
Synapse has enriched 10 related papers. Consider them for comparative context: